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ABSTRACT
Acrolein is an electrophilic α, β-unsaturated aldehyde. Additionally, acrolein is a
metabolite of the antineoplastic alkylating agent cyclophosphamide and is implicated in off-target
effects, including to bladder hemorrhagic cystitis and cyclophosphamide-induced cardiotoxicity,
both of which have led to serious secondary iatrogenic injury during and following chemotherapy.
At low concentrations acrolein inhibits cell proliferation without inducing apoptosis, while at high
concentrations may result in secondary apoptosis promotion. This investigation assessed the role
of the enzyme poly (ADP-ribose) polymerase (PARP) in acrolein induced toxicity using the
established toxicological H9c2 (2-1) cardiomyoblast in vitro model. H9c2 (2-1) cells were plated
in 24-well plates at 75,000 cells per well three days prior to testing, followed by acrolein dosing
at concentrations between 10 µM and 1000µM for either 30 or 55 minutes. PARP activity was
quantitatively measured in total cell lysates using a biotin-avidin-conjugated horseradish
peroxidase-TMB reporter system in a 96-well microplate formate. The lowest effective dose of
toxicity at 30 minute dosing was found at 25 μM (PARP Activity 1.65-fold control) which returned
to baseline at 100 μM; concentrations at or above 250 μM results in significant PARP activity
reductions (≤ 0.46-fold control). Biomarkers were further characterized for cytotoxicity (AST
presence), and viability (MTT reduction) in order to facilitate mechanistic characterization of
PARP-mediated acrolein cardiotoxicity. Investigation of a PARP inhibitor was assessed to explore
the intervention for acrolein induced cardiac tissue damage.
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CHAPTER ONE:
INTRODUCTION
Acrolein
Acrolein (C3H4O, CAS No. 107-02-8) is a α,β-unsaturated aldehyde which is extremely
electrophilic. According to the American Cancer Society 1:8 or 12% of women in America will
develop breast cancer within their lifetime, excluding skin cancers breast cancer is the most
common cancer of women in America (American Cancer Society, 2016). Cyclophosphamide as
an antitumor prodrug is commonly used for treatment of broad spectrum human cancers.
Routinely, it is most prescribed for treatment of breast cancers, ovarian cancers and lymphomas
(Chan, 1984).

Cyclophosphamide is itself inactive, thus requiring an enzyme mediated

bioactivation to induce cytostatic activity. As a prodrug cyclophosphamide is categorized as an
alkyling agent, once it undergoes activation it forms aldophosphamide. The active metabolite of
cyclophosphamide is phosphoramide mustard and the toxic metabolite is acrolein both are
produced during biotransformation of aldophosphamide (Conklin et al., 2015). Phosphoramide
mustard, uses ion intermediates to help with inhibition of DNA replication and activation of
apoptotic pathways. This is accomplished by phosphoramide mustard creating DNA crosslinks
(interstrand/intrastrand) at the 7-nitrogen atom which initiates cellular death pathways. As a biproduct of the transformation of aldophosphamide into phosphoramide mustard acrolein is also
formed (de Jonge, Huitema, Rodenhuis, & Beijnen, 2005). Like many other metabolites derived
through phase II xenobiotic metabolism, acrolein is far more toxic than its derivative
cyclophosphamide. Acrolein as an electrophilic α, β-unsaturated aldehyde, is implicated in off1

target effects including bladder hemorrhagic cystitis and cardiotoxicity. Due to its electrophilic
nature acrolein is highly capable of reacting rapidly at several cellular sites, coupled with its
cellular irritation effects , its presence proves to be a highly problematic and is attributed with
being the main source cyclophosphamide treatment toxicity (Kehrer & Biswal, 2000). At low
concentrations acrolein inhibits cell proliferation without inducing apoptosis, while at high
concentrations its presence may result in secondary apoptosis promotion (Mohammad et al., 2012).
Select chemotherapeutic drugs are associated with several cardiotoxic side effects.
Complications transverse a wide spectrum but more common side effects of chemotherapeutic
treatment include pericarditis, isolated arrhythmias, myocarditis, cardiomyopathy, and cardiac
failure. Risk factors associated with individuals developing cardiotoxicity pose treatment of a
chemotherapeutic drug is directly associated with the cumulative dose per treatment. Alkylating
agents contradict anthracycline agents which follow a dose-response dependent relationship or
lifetime dose. Incidences of disease are highly dependent upon a dose-concentration per
administration (Dadfarmay, Berkowitz, & Kim, 2012). High dose concentrations of
cyclophosphamide therapy can result in cardiac toxicity. High dose concentrations are defined as
144-270 mg/kg, administration at these level can lead to death which is endorsed by heart failure
(Chan, 1984). Doses attributed with a 25% incidence of cardiotoxicity are ~ 240mg/kg, although
cardiac toxicity has been seen in dosage as low as 144 mg/kg. Cyclophosphamides clinical
manifestations of cardiotoxicity include arrhythmias, cardiac enzymes elevation, congestive heart
failure, electrocardiographic voltages dampening, pericarditis and transient cardiomegaly
(Langford, 1997). Current data on cardiotoxicity of cyclophosphamide shows a need for
developing intervention methods to help mitigate the damages of acrolein induced toxicity.
Administration of cyclophosphamide at high treatment levels is associated with acute-cardio-
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toxicity. This associated toxicity has shown that GSH plays an integral role in protection against
cardio-toxicity, acrolein prompted glutathione depletion is tied to cyclophosphamide associated
cardiotoxicity (de Jonge et al., 2005).

H9c2(2-1) Model
A century has passed since Ross Harrison completed the first successful culturing of cells,
leading him to be known as the father of cell culture. Although cell culturing techniques began in
the 20th century, techniques continue to evolve and advance today (Rodriquez-Hernandez, 2014).
The establishment of the H9c2 line in the 1970’s has proven that this cell model is useful for
utilization in toxicological testing.

The H9c2 (2-1) is a myoblast sub-clone derived from

embryonic BDIX rat heart tissue the original clonal line developed by B. Brandt and B. Kimes
(Hescheler et al., 1991). The H9c2 (2-1) cell line is largely valuable when compared to primary
cultures or whole tissues due to its ability to remain more homogenous phenotypically, this
stability transcends electrophysiology, morphology and biochemistry properties. These
characteristics help make the H9c2 (2-1) cell line an excellent model choice when studying cellular
development or cellular death. Studying culturing conditions has shown the H9c2 (2-1) cell line
successively propagates for months without undergoing any characteristic changes (Kimes &
Brandt, 1976). The H9c2 (2-1) cell line is proven in-vitro model for studying cardiac and skeletal
muscle. Additionally it is invaluable model due to its ability to remain a myoblast when serum
concentration are supported, providing multiple generations for testing helping to reduce the need
for controlling batch variation. The ability to test H9c2 cells within a reasonable propagation
range help to ensure treatment is performed on cells similar in terms viability, morphology, and
biological properties. The H9c2 (2-1) cell line is also valuable due to its ability to differentiate
when serum concentration are reduced allowing the newly differentiated cells to contain several
3

elements of cardiac cells. These similarities allow differentiated cells to be used for testing
cardiovascular diseases, including the assessment of preventative measures and mechanistic
pathways (Sardao, Oliveira, Holy, Oliveira, & Wallace, 2007). The in-vitro model for H9c2 cells
is currently used to evaluate and manipulate signaling pathways, cellular mechanism, and
enzymatic signaling involved in cardiotoxicity. More specifically the use of H9c2 (2-1) cells lines
has helped to distinguish drug-induced cardiotoxicity characteristics along with possible
intervention methods (Aboutabl & El-Kadi, 2007). In recent studies the H9c2 model has confirmed
that cultured primary cardiomyocytes have the ability to be used for studying the hearts metabolic
capacity. Stemming from these results the H9c2 cell line was also assessed for its ability to be used
as an in-vitro model for heart enzymes associated with drug metabolism. The authors were able to
show that expression of CYP1A1 and 1B1 occurs in H9c2 cell lines, additionally the expression
can be manipulated through the addition of an inducer (Zordoky & El-Kadi, 2007). Studies have
also shown that cellular viability of the H9c2 cell line can be measured by using 3-(4,5Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) levels (Aboutabl & El-Kadi,
2007).

Poly(ADP-Ribose) Polymerase
Current knowledge of enzyme family of Poly(ADP-Ribose) Polymerase (PARPs) has led
to the discovery of 18 known members, each varies based on cellular function, molecular weight,
composition, location, but all have conservation that is supported by ADP-ribosylating catalytic
domain. Poly(ADP-Ribose) polymerase is classified as a chromatin-associated nuclear enzyme,
its activation occurs due to DNA damage. DNA repair is an extremely energy-dependent process
and apoptosis is an extremely energy-dependent process. As DNA damage is assessed and
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repaired, cellular energy will be depleted based on the extent of the damage. An integral part of
the process is carried out by the DNA repair enzyme poly(ADP-Ribose) Polymerase. PARP
activation occurs when a cell undergoes DNA damage, typically in the form of strand breaks (Jin
& El-Deiry, 2005). Through the attachment of poly(ADP-Ribose) units the cell can modify nuclear
proteins. Activated PARP leads to poly(ADP-Ribosyl)ation of many cellular proteins (histones,
DNA, topoisomerases I & II, PARP) protein activation in turn leads to activation of different
pathways (Kaplan, O'Connor, Hake, & Zingarelli, 2005). Poly(ADP-Ribose) polymerase as an
enzyme works by detecting DNA strand breakage. After detection of DNA damage PARP
catalyzes ADP-ribose transfer from co-enzyme NAD+ to help bind DNA. (Dantzer et al., 1999)
Cellular damage can occur directly though genotoxic agents (oxidation, ionization, alkylation) or
as an indirect process post-enzymatic incision. Cellular viability is highly dependent upon the
energy depletion as cells undergo repair processes.
PARP-1 which is the most abundant isoform of PARP in the human body is found in the
nucleus of the cell, its main function is the detections of single-stranded DNA breaks (SSB).
PARP-1 also plays an integral role in cell death, over-activation of PARP-1 leads to significant
genomic stress thus causing extreme cellular inflammation due to ATP & NAD depletion
(Rouleau, Patel, Hendzel, Kaufmann, & Poirier, 2010). These energy depletions will lead the cell
to undergo cellular death through necrosis. Previous studies have confirmed a direct inverse
relationship between NAD+ and PARP. Decrement of NAD+ effect cellular glycolysis including
the Krebs cycle and the redox state of cells (Bouchard, Rouleau, & Poirier, 2003). PARP-1 is
also attributed to causing cellular death through apoptosis, this can occur through several processes
including caspase-dependent apoptosis, factor-mediated, and caspase-independent apoptosis.
Additionally PARP-1 interaction with a down-stream cell death effector (PAR polymer) leads to
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parthanatos cell death. PARPs role in all forms of cellular death including programmed, necrosis
and apoptosis is dependent upon the amount of PARP activation, pathway selection, cellular
metabolic status, and intervention factors (Rosado, Bennici, Novelli, & Pioli, 2013). The
difference between apoptosis and necrosis is determined by biochemical and morphological
features. Necrosis is defined as the occurrence of cell death as a consequence of acute damage
due to disease or injury which lead to an inflammatory response. Apoptosis is characterized as a
programmed cell death (Hong, Dawson, & Dawson, 2004). Early phase apoptosis is triggered
when transient PARP activation occurs (pre-caspase-mediated-cleavage) and is controlled by the
integral relationship between PARP and poly(ADP-ribosyl)ation. PARP as an important
determinant of programmed cell death is responsible for inhibiting or selection apoptosis or
necrosis pathways. During apoptosis PARP cleavage occurs parallel to caspase activation. PARP
cleavage is believed to be responsible for the depletion of energy needed in late-stage apoptosis
(Herceg & Wang, 2001). Within apoptosis and necrosis there are well defined cell death processes
which are unique to injury induction and cell type. PARP-1 is responsible for PARP-1 mediated
apoptosis-inducing factor (AIF). This pathway is linked to ischemic injury and excitotoxic cell
death. Hypothesis for PARP-1 mediated cell death involves the rapid depletion of cellular ATP
and NAD+ due to the over activation of PARP. The reduction of these energy sources affects
cellular metabolism and lead to apoptosis. Cell death is heavily dependent upon mitochondria
(cellular powerhouse) and nucleus (DNA) health. When either of these organelles is damaged
beyond repair signaling determines cellular death pathways, which are dependent upon PARP
(Hong et al., 2004).
Clinical trials are evaluating PARP-1 inhibitors’ ability to be used as a therapeutic agents,
primarily for tertiary care of cancers, inflammatory and autoimmune diseases. The use of an
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inhibitor is proving beneficial due the role of PARP in DNA damage detection and base excision
repair. PARP inhibitors have been shown through several experimental models to have protective
effects against acute and chronic inflammatory diseases (Rosado et al., 2013). In-vitro studies
have shown that use of a PARP inhibitor helps render a cell resistant to death by certain inducers,
one of which including alkylating agents. These same studies demonstrated that PARP inhibition
has shown protective for skeletal muscular and cardiac tissues when ischemia reperfusion was the
attributed cause of damage (Herceg & Wang, 2001). PARP inhibitors are chemical agents that are
designed to compete at the enzyme activation cites with NAD+. When a PARP inhibitor is
introduced it acts as a competitive agent against PARP, preventing the repair of DNA damage
(Rouleau et al., 2010).

DIQ 1,5-dihydroxyisoquinoline
DIQ 1,5-dihydroxyisoquinoline (C9H7NO2

CAS No. 5154-02-9) is a potent PARP

inhibitor that is activated by nitric oxide. Previous studies have shown 1,5-dihydroxyisoquinoline
(DIQ) to have a high selectivity for PARP inhibition, pharmacological studies have shown this
inhibition helps with the reduction of myocardial damage and increases the viability of cells by
inhibiting apoptosis. In-vivo studies of rats which were treated with DIQ showed that PARP-1
inhibition resulted in reduction of infarct size and significant cardio protection, especially in
reperfusion linked injury. DIQ has been shown to inhibit PARP –induced inflammatory responses
which lead to cells undergoing necrosis (Kaplan et al., 2005). PARP inhibitors have also shown
that following a sublethal-treatment of alkylating agents have the ability to suppress certain
signaling pathways driving the damaged cell towards apoptosis instead of necrosis. This is further
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characterized through PARP cleavage and PARPs inactivation by caspase-3, both of which are
proven markers of that the damaged cell has undergone apoptosis (Dantzer et al., 1999).
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CHAPTER TWO:
METHODS
Cell Culture
H9c2(2-1) Rat Embryonic Myoblasts cell line were obtained from the American Type
Culture Collect (ATCC) (Manassa, VA) and cultured under humidified conditions, with a 5% CO2
at 37°C.

Cellular medium consisted of Debulcco’s Modified Essential Medium (DMEM)

(Corning, Manassa, VA) containing 1% - 100U/mL and100mg/mL penicillin and streptomycin,
10% fetal bovine serum (ATCC), and 1% L-glutamine. (Zordoky & El-Kadi, 2007) Every twothree days medium was changed to provide cells with fresh nutrients. Subdivision of cells occurred
when plates reached 80-90% confluence to maintain cells exponential growth. Subdivision was
performed by aspirating then washing the plates with phosphate buffered saline (PBS) without
calcium or magnesium (Corning) followed with a light trypsinization [0.1% Trypsin EDTA in PBS
(Corning)] incubated at 37°C for 5 minutes. The trypsinization reaction was stopped through
adding a 1:1 of DMEM, cells were then separated through centrifugation at 250 x g for 4 minutes.
Post-centrifugation, supernatant was aspirated allowing resuspension of cells with fresh DMEM.
Cells were either plated in tissue-culture treated plates for testing or re-plated to continue
propagation. The H9c2(2-1) cells used for experimentation fell within the 5th -12th passage to help
ensure stability, consistency and reduce the likelihood of genotype-variation. Exposure periods
would only occur after allowing cells sufficient time to reattach to plates, time periods were
determined by analysis performed.
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Treatment
H9c2(2-1) cells were plated into tissue culture-treated microplates at 1,000 cells per well
(96-well) or 75,000 cells per well (24-well) 72 hours prior to MTT or PARP activity assessment,
respectively. For AST cells were plated at 10,000 cells per well into 96-well plates 48 hours prior
to activity assessment. To prepare for biological marker experimentation, cell were aspirated,
washed, and underwent a 30 minute pre-incubation with either a vehicle or PARP inhibitor. PARP
inhibitor groups received 100 µM DIQ 30 minutes prior to dosing, and paired with vehicle-only
(DMSO) controls. Replacement medium contained either a 0.3% vehicle (DMSO) or 0.3% PARP
inhibitor DIQ. Cells were then underwent a 30 minute exposure period with or without the PARP
inhibitor DIQ with acrolein at concentrations varying between 10 µM and 1000 µM; controls
received medium containing hydroquinone at the same dilution as the 1000 µM acrolein group.
For PARP assay experimentation cells were not treated with PARP inhibitor, cells were treated
with acrolein only at two time points, 30 or 55 minutes respectively. For MTT and AST cells
underwent a 30 minute pre-incubation with either a vehicle or PARP inhibitor, cells were then
underwent a 30 minute acrolein exposure followed by a wash out period. MTT and AST test were
given a 100 mM DIQ PARP inhibitor and then groups were treated with acrolein at concentrations
varying between 10 µM and 1000 µM.

Poly(ADP-Ribose) Polymerase Activity
For PARP activity assessment, cells were treated with acrolein for 30 or 55 minutes, lysed
in a PARP stabilizing buffer, and protein quantified via the Bradford method. A 10X stock solution
which was diluted down to 1X PARP stabilizing buffer, was iced, and mixed with samples on ice.
Each 24-well plate was iced and then received 75 µl of cold 1X PARP buffer per well. PARP lysis
10

buffer is made fresh each treatment day by diluting down from a 10X stock PARP buffer solution.
The 10X PARP buffer solution consisted of tris base (500 mM), magnesium chloride
MgCl2·6H2O (20 mM), triton x-100 (1% or 0.01), bovine serum albumin (1000 μg/mL),
hydrochloric acid HCl (1.78 M pH to 8.00), and autoclaved U.P. H2O to bring to final volume.
For PARP analysis protein quantification was used to set all samples to the required 8 µg of
protein. The Bradford Reagent was prepared using Marion M. Bradford’s recipe of dissolving 100
mg of Coomassie Blue into 50 ml of 95% ethanol solution, additionally 100 ml of 85% phosphoric
acid solution was added. The final solution was then diluted down into a 1 liter total volume
solution. The Bradford Reagent final concentrations are 0.01% Coomassie Blue (w/v), 8.5%
phosphoric acid (w/v) and 4.7% ethanol (w/v). (Bradford, 1976). This solution then underwent
double filtration before being used for protein quantification of PARP lysis samples. Standards
used to build the curve for protein quantification included 2,000 / 1,000 /500, 250, 125, 65.5, 31.25,
15.625 and 0. These standards were built using the bovine serum albumin (BSA) albumin standard
ampules provided in the BCA protein assay kit (Thermo Fisher). Standards and samples were run
in duplicates and read via UV-VIS spectrophotometer at 595 nm. Raw data for each duplicate was
averaged, blanked and quantified to determine the dilution concentration to standardize all samples
to 8 µg protein for loading in the in house PARP assay.
To evaluate Poly(ADP-Ribose) Polymerase activity and in house PARP Assay was used
which uses a quantitative colorimetric endpoint. The protocol for this assay spans across a three
day period. On the first day a high binding 96-well plate (Fisher -Perkin Eelmer) is prepared to
plate histones. A histone plating solution is made and then 50 μL of histone plating solution is
added to each well. The histone plating solution consists of 90 mM sodium carbonateNa2CO3, 10
mM sodium bicarbonateNaHCO3, histone solution 0.1 mg/ml and autoclaved U.P. H2O (to bring
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to final volume). After each well receives the plating solution the plate is sealed with parafilm and
incubated overnight at 4°C to allow the histones to adhere to the plate. The second day involves
blocking the plate. The plate undergoes a series of washes with each wash including a 5 minute
incubation period at 23°C. The first wash solution consists of Phosphate Buffered Saline
supplemented with 0.05% Tween-20 (PBS-T), 200 µl/well the wash is repeated twice. The second
wash solution consists of Phosphate Buffered Saline (PBS), 200 µl/well also repeated twice.
Following the final wash a 3% BSA blocking buffer is added to each well followed by an overnight
incubation at 4°C. The third day of this assay involves the detection of PARP.
PARP activity was assessed using 8 µg of lysate, based on the results of the Bradford
protein quantification. Preparation of samples included dilution in 1X PARP buffer prepared on
ice, PARP HAS standards for determining calibration curve are also diluted using 1X PARP buffer
prepared on ice. A working PARP cocktail solution is prepared immediately prior to use. This
solution is diluted down from a 10X PARP cocktail stored in -20°C into a 1:10 solution using
autoclaved U.P. H2O. The 10X PARP cocktail contains NAD+ and Biotinylated-NAD; the sum of
both NAD+/B in the 1X working reagent is 3 mM. Immediately prior to use a 1:10 of Sheared
Herring Sperm DNA is added into 1X PARP cocktail. Once all cocktails and samples have been
prepared the plate is removed from the 4°C refrigerator and undergoes two wash cycles of 200 μL
of PBS-T and PBS repeating the wash regime from day 2. Post washing 25 μL of PARP HSA
standards and samples were added in duplicates to their respective wells, this is followed by the
addition of 25 μL of 1X PARP cocktail. Mixing occurs via tapping followed by a 60 minute
incubation at 21°C. Following PARP cocktail incubation plates are washed 3 times consecutively
each with PBS-T and PBS. Post washing 50 μL of 1:60,000 Streptavidin-HRP is added, mixed,
and then incubated at 21°C for 60 minutes. Following Streptavidin-HRP incubation plates are
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washed 3 times consecutively each with PBS-T and PBS. Post washing 50 μL 3,3',5,5'Tetramethylbenzidine (TMB) is added in the dark to each well, incubation occurs for 30 minutes
at 21°C. Wells will turn bright blue based on PARP activity. Post incubation 65 μL of 0.2M
hydrochloric acid is used to stop the reaction. Plates are mixed and then stand for 10 minutes before
being read via UV-VIS spectrophotometer at 412 nm.
Cytotoxicity Assessment

MTT, 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide
For MTT activity assessment, cells were plated at 1,000 cells per well (96-well), pre
incubated with DMSO or DIQ and then treated with acrolein for 30 minutes. Standards were ran
in triplicates, while samples were ran in 6 replicates. Standard curve was built by plating at 2,000/
1,500/ 1,000/ 800, 600,400,200 and a DMEM blank. Samples were aspirated, washed, and
replaced with 50 μL DMEM containing 0.3% DIQ or 0.3% DMSO for a 30 minute pre-incubation.
Post incubation samples were treated with 50 μL DMEM containing acrolein at concentrations
varying between 10 µM and 1000 µM; controls received medium containing hydroquinone at the
same dilution as the 1000 µM acrolein group. Following treatment cells were aspirated, washed,
and replaced with 50 μL fresh DMEM followed by a 4 hour wash-out period. Thereafter, cells
were incubated for 2 hours with MTT at a 1:10 dilution at standard culturing conditions. MTTsupplemented medium was then replaced with 100 μL DMSO in order to solubilize the reduced
formazan in preparation for UV-VIS measurement at 570 nm. For analysis standards were blanked
against DMEM, samples were blanked against DMEM containing 0.3% hydroquinone solution.
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AST, Aspartate Aminotransferase
For AST cells were plated at 10,000 cells per well (96-well). Samples were run in
triplicates, they were aspirated, washed, and replaced with 50 μL DMEM containing 0.3% DIQ or
0.3% DMSO for a 30 minute pre-incubation. Post incubation samples were treated with 50 μL
DMEM containing acrolein at concentrations varying between 10 µM and 1000 µM; controls
received medium containing hydroquinone at the same dilution as the 1000 µM acrolein group.
Following treatment cells were aspirated, washed, and replaced with 35 μL fresh DMEM followed
by a 6 hour wash-out period. Thereafter, 10 μL medium of sample was re-plated in duplicates into
a new 96-well plate. Each well plate contained standards, blanks, and AST calibrator also plated
at 10 μL in duplicates. The standard curve was derived using Oxaloacetate diluted in PBS to 10
μM then serially diluted to 5μM, 2.5mM 1μM, 0.5μM, 0.25μM, 0.125μM. Once all standards,
samples, blanks and calibrator were plated 50 μL AST Substrate was added every 10 seconds using
a multichannel pipette. Plates were then incubated for 10 minutes at 37°C. Following substrate
incubation 50 μL AST color developer was added every 10 seconds using a multichannel pipette.
Plates were again incubated for 10 minutes at 37°C. Finally 100 μL 0.2M HCL was added using a
multichannel pipette. Plates were then incubated for 10 minutes at 21°C. Thereafter, samples were
ran in UV-VIS measurement at 530 nm. For analysis standards were blanked against PBS while
samples were blanked against DMEM. Quantified results were converted using 78.8 IU/L to
standardize AST signal.

Spectrophotometric Quantification
Assays which required assessment of colorimetric endpoints (AST, MTT, and PARP) were
quantified using the µQuant Spectrophotometer (BioTek, Winooski, VT) coupled with the KC-
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Junior Analytical software (BioTek). Each colorimetric endpoint that was assessed was set at the
wavelength suggested by the manufacturer. Assays were read via UV-VIS spectrophotometer at:
PARP 412 nm, MTT 570 nm, and AST 530 nm.

Statistical Analysis
Statistical analysis was performed utilizing Microsoft Excel. Standards were averaged,
blanked and quantified to be used for analyzing samples. Samples were averaged, blanked, and
used standards quadratic equation to be quantified. Additional analysis was performed to derive
fold and standard deviation values. Fold averages and fold deviations were further analyzed by
aggregating all of the test to determine each treatment group’s average, standard deviation, 95%
confidence interval and t-test. Aggregated data was processed using SPSS predictive analytics
software to identify and eliminate outliers. Outliers were classified as falling 3 standard deviations
below/above the standard mean. Statistical significance was determined when the probability of
reaching the measured statistic fell at or below 5.0 % (p ≤ 0.05).
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CHAPTER THREE:
RESULTS
Summary: Cytotoxicity
Looking at the H9c2 (2-1) cell line as an in-vitro model is beneficial for analyzing the role
that Poly(ADP-Ribose) Polymerase and PARP inhibitors play in acrolein induced-cytotoxicity. In
assessing poly(ADP-ribose) polymerase activity post treatment across two time points it was
apparent that a treatment-dependent relationship was demonstrated when assessing PARP activity
against acrolein concentration. For this analysis two bio-markers of cytotoxicity were utilized to
interpret the degree of cellular death post treatment. First cellular viability was assed using the
mitochondrial succinate dehydrogenase-dependent MTT reduction assay.

Then aspartate

aminotransferase (AST) assay was used to measure colorimetric analysis in units/liter (U/L) the
reaction between each lysates’ enzyme and substrate. Aspartate aminotransferase was able to
provide evidence of membrane degradation, cellular damage and ultimately viability offering a
comparison between treatment and vehicle medium. While signal strength was week and fell
below detection limits in lower treatment groups the AST assay still represented a relevant toxic
endpoint. Both of these assays demonstrated DIQ’s ability to increase cellular viability, although
statistical significance was only reached in two treatment groups.

Poly(ADP-Ribose) Polymerase Activity
To prepare for PARP analysis 75,000 cells were plated into 24-well plate to allow for a 30
minute or 55 minute time exposure to acrolein treatment groups varying in concentrations of 10
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µM-1000µM. Post exposure, cells were washed using PBS and lysed using a prepared ice-cold
lysis buffer which was supplemented with Triton-X-100. Lysis of cells occurred over ice and
protein lysates were collected in triplicates, with one being used for quantification via Bradford
method. For the PARP assay the amount of purified cellular protein required was standardized to
8 micrograms per sample. The standard curve was calibrated and quantified for further analysis
of PARP activity in samples. Samples duplicates were first averaged, blanked and then quantified
against the quadratic equation generated by the standards. This created an x-axis of PARP activity
in 8 µg against the y-axis of treatment groups. The lowest effective concentration of toxicity at 30
minute exposure was found at 25 μM (PARP Activity 1.65-fold control) [Figure 1.] which returned
to baseline at 100 μM; concentrations at or above 250 μM results in significant PARP activity
reductions (≤ 0.46-fold control). This evidence suggests that acrolein induced cardiotoxicity may
be modulated through PARP inhibition. . There was no lowest effective concentration of toxicity
at 55 minute exposure. [Figure 2.] All concentrations when compared to control results had
significant PARP activity reductions (≤ 0.98-fold control). This evidence suggests that acrolein
induced cardiotoxicity may be modulated through PARP inhibition, but against longer exposure
periods samples folds will significantly reduce linearly with time. [Figure 3.]
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PARP Activity-Acrolein 30 Minute Exposure
PARP Activity (Fold Control)

2.0

*

*

1.5

1.0

*

0.5

*

*

500 μM

1000 μM

0.0
10 μM

Control

25 μM

Error Bars = Standard Deviation
*p<0.05 Compared to Control
n=9-10 Samples per Dose Group

50 μM

100 μM

250 μM

Acrolein Concentration Group

Figure 1: Poly(ADP-Ribose) Activity 30 Minutes: PARP Activity (fold-control) assessed 30 minutes after exposure
with acrolein. Two positive statistical significant differences were observed when compared to control in the 25 μM
& 50 μM treatment groups. All treatment groups ≥250 μM reached negative statistical significance when compared
to fold control.

PARP Activity - Acrolein 55 Minute Exposure

PARP Activity (Fold Control)

2.00

1.50

1.00

0.50

0.00
Control

10 μM

Error Bars = Standard Deviation
No Doses reached Significance due to
Control Variability
n=9-12 Samples per Dose Group

25 μM

50 μM

100 μM

250 μM

500 μM

1000 μM

Acrolein Concentration Group

Figure 2: Poly(ADP-Ribose) Activity 55 Minutes: PARP Activity (fold-control) assessed 55 minutes after exposure
with acrolein. No treatment groups reached statistical significant All treatment groups ≥10 μM had PARP activity that
fell below fold control.
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PARP Activity (Fold Control)

PARP Activity - Acrolein Exposure for 30 and 55 Minutes
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Figure 3: Poly(ADP-Ribose) Activity Comparison: PARP Activity (fold-control) assessed at 30 & 55 minutes after
exposure with acrolein. Only treatment groups at the 30 minute time point reached positive/negative statistical
significance. At either time point acrolein treatment groups ≥250 μM had PARP activity that fell below fold control.

Toxicological Endpoints
MTT, 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide
To prepare for MTT analysis 1,000 cells were plated into 96-well plate to allow for a 30
minute time exposure to acrolein treatment groups varying in concentrations of 10 µM-1000µM.
Post exposure, cells were washed using PBS, underwent a 4 hour wash out, and then had medium
replaced with 1:10 dilution of formazin for a 2 hour incubation. Cells were then aspirated and
formazin crystals were re- solubilized using DMSO. The MTT analysis was preformed through a
colorimetric assay which was used to determine the amount of cellular enzyme activity present
based on the amount tetrazolium dye reduced. The reduction produces an insoluble formazan
which is re-solubilized to produce a purple color. Based on the color gradient read via UV-VIS
spectrophotometer cytotoxicity can be assessed (Riss et al., 2004). Standard curves were built
using cell plating ranging from 200-2,000 cells, readings were calibrated then quantified for further
analysis of MTT activity in samples. Treatment groups duplicates were averaged, blanked and
then quantified against the standards. In MTT the concentrations of toxicity for acrolein which the
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DIQ treatment had the greatest protection was found at 25 μM & 50 μM when comparing to the
vehicle in the MTT analysis. (MTT Activity 0.05 & 0.003 T-Test) [Figure 4.] At ≥250 μM DIQ
provided no significant protections (MTT Activity 0.119, 0.527, 0.463 T-Test). At ≤100 μM DIQ
protection was limited (MTT Activity 0.065 T-Test). Statistical analysis was further assessed to
determine if any outliers were skewing data results. Treatment groups’ data were assessed by either
vehicle or DIQ. In vehicle treatment groups (DMSO) two outliers were assessed. [Figure 5.] After
their removal standard deviations in the 100 μM & 1000 μM reduced. (100 μM 0.37 -> 0.21 &
1000 μM 0.05 -> 0.03) In PARP inhibitor treatment groups (DIQ) two outliers were assessed.
[Figure 6.] After their removal standard deviations in the 25 μM & 50 μM decreased. (25 μM 0.28
-> 0.16 & 50 μM 0.25 -> 0.12)

Figure 4: MTT Activity: MTT Activity (fold-control) assessed 30 minutes after exposure with acrolein. Two positive
statistically significant differences were observed when compared to control in the 25 μM & 50 μM treatment groups.
All treatment groups ≥250 μM showed some protections but none reached statistical significance when compared to
fold control. At ≤100 μM DIQ protection was limited
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Fold Average
Fold Average

Figure 5: Vehicle Box Plot MTT: Outliers were processed using SPSS predictive analytics software. Circles noted
in reader results denote outliers. Outliers were processed using aggregated fold averages for all trials. °37 Fell under
Trial 5 -100 μM treatment group. The fold value .53 fell more than 3 standard deviations above the average after its
removal from the data set so its value was thrown out. . °64 Fell under Trial 8 -1000 μM treatment group. The fold
value .14 fell more than 3 standard deviations above the average after its removal from the data set so its value was
thrown out.

Figure 6: DIQ Box Plot MTT: Outliers were processed using SPSS predictive analytics software. Circles noted in
reader results denote outliers. Outliers were processed using aggregated fold averages for all trials. °20 Fell under
Trial 4 -25 μM treatment group. The fold value .33 fell more than 3 standard deviations below the average after its
removal from the data set so its value was thrown out. . °28 Fell under Trial 4 -50 μM treatment group. The fold value
.22 fell more than 3 standard deviations below the average after its removal from the data set so its value was thrown
out.

AST, Aspartate Aminotransferase
To prepare for AST analysis 10,000 cells were plated into 96-well plate treated at groups varying
in concentrations of 10 µM-1000µM for a 30 minute exposure period. Post exposure, cells were
washed using PBS, underwent a 6 hour wash out with fresh medium, and then had 10 µl of lysate
medium collected and replated in duplicate into a new 96-well plate. In this assay glutamate
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oxaloacetate transaminase (GOT) is reduced using tetrazolium enzymatic reaction with oxalacetic
acid yielding a red compound to be read and standardized against a calibrator. Standard curves
were built using Oxaloacetate ranging from 10 μM -0.125μM. Samples underwent substrate, color
developer, and HCL incubations prior to being read via UV-VIS spectrophotometer. For AST the
only treatment groups which were read above the detection limits were ≥ 250 μM. No AST
treatment concentrations reached Significance due to control Variability, at 250 μM & 500 μM
DIQ protection was limited (AST Activity 0.09 & 0.26 T-Test). In 1000 μM DIQ treatment groups
an adverse effect was seen in vehicle treatment groups having higher viability. (AST Activity
0.175 t-test) [Figure 7.] Further statistical analysis was performed using SPSS to determine if any
outliers existed for trials. Data was aggregated by either vehicle or DIQ. Statistical analysis was
further assessed to determine if any outliers were skewing data results. Treatment groups’ data
were assessed by either vehicle or DIQ. In vehicle treatment groups (DMSO) no outliers were
present. [Figure 8.] In PARP inhibitor treatment groups (DIQ) no outliers were present. [Figure
9.]
AST Activity- Acrolein 30 Minute Exposure
0.4

AST Activity IU/L

0.35
0.3

0.25
0.2
0.15
0.1

0.05
0
-0.05

1000

500

250

0

Acrolein Concentration Group (µM)
Erro r Bars = Stan dard Dev iation
No Do ses reached Significan ce du e to
Co n tro l Variability
* p < 0 .05 Compared to Contro l

Vehicle (DMSO)

DIQ

Figure 7: Aspartate Aminotransferase Activity AST Activity (fold-control) assessed 30 minutes after exposure
with acrolein. No treatment groups reached statistical significance due to control variability.
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Fold Average
Fold Average

Figure 8: Vehicle Box Plot AST: Outliers were processed using SPSS predictive analytics software. Circles noted in
reader results denote outliers. No outliers were detected.

Figure 9: DIQ Box Plot AST: Outliers were processed using SPSS predictive analytics software. Circles noted in
reader results denote outliers. No outliers were detected.
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CHAPTER FOUR:
DISCUSSION
This investigation explored the role of Acrolein-induced Toxicity using the H9c2 model,
and what role PARP inhibitors play in helping reduce cytotoxicity. Chemotherapy induced cardiotoxicity is a well-documented side effect of undergoing prodrug treatments. Cardiotoxicity due to
molecular mechanisms of oxidative stress can lead to apoptosis due to cytotoxicity (Angsutararux,
Luanpitpong, & Issaragrisil, 2015). Cytotoxic potentials of cyclophosphamide and acrolein are
being assessed at in-vivo and in-vitro levels. Understanding the mechanistic differences between
administrations of toxicants of cellular vs. whole systems is important for furthering research into
preventative measures. Cyclophosphamides toxicity is greatest after it has undergone microsomal
oxidation generating acrolein, the cytotoxic aldehyde (Sladek, 1973).

Cyclophosphamide

activation forms 4-hydroxycyclophosphamide, which is readily diffused within cells and is not a
cytotoxic compound. It does spontaneously decompose due to being incredibly instable leading to
the formation of phosphoramide mustard and acrolein. Acrolein is highly reactive aldehyde,
making it extremely cytotoxic. Previous studies have contributed ATP reduction as a major
contributor to acrolein-mediated necrosis. Possible explanations for the depletion of ATP include
the over-activation of PARP, thus leading to reduced ATP because of the energy taking process of
PARP’s substrate regeneration (Kern & Kehrer, 2002). Another possibility for the enhanced
cytotoxicity of acrolein is glutathione depletion at the cellular level due to conjugation (de Jonge
et al., 2005). Previous studies have supported that mitochondria lack glutathione biosynthesis
enzymes, thus GSH must be transported from the cytosol into the mitochondria by using a high
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affinity transporter. This means that acrolein conjugation leads to the depletion of glutathione not
GSH oxidation (Arumugam, Thanislass, Ragunath, Niranjali Devaraj, & Devaraj, 1999). Previous
studies have also linked the unsaturated nature of acrolein as the cause for the stark depletion of
cytosolic glutathione, in-vivo rat studies have shown an unchanged content of GSSG in acroleintreated rats, and thus GSH oxidation pathways went unused (Arumugam et al., 1999). Potential
biomarkers have been identified and could be used to assess the amount of acrolein conjugation
occurring in individuals’ undergoing chemotherapy treatments of cyclophosphamide. Conjugation
of glutathione with acrolein produces 3-hydroxypropylmercapturic acid. Previous studies have
found that 3-hydroxypropylmercapturic acid is detectable through urinalysis of individuals and
rats

treated

with

cyclophosphamide

(Faroon

et

al.,

2008).

The

ability

of

3-

hydroxypropylmercapturic acid production as a measurement tool for elucidating the amount of
acrolein bi-product produced from chemotherapy treatments should be further assessed.
PARP-1 activation is responsible for mediation of cell death, through signaling
downstream apoptotic effectors. PARP-1 activation has been proven to mediate pathways for cells
which underwent damage induced through reperfusion injury, reactive oxygen species injury,
inflammatory injury, and ischemia injury (Yu et al., 2002). PARP inhibitors are undergoing
clinical development to be used as a therapeutic agent. Currently a two-pronged approach is being
utilized. First is the targeting of cells that have a genetic predisposition toward death when PARP
activity is inhibited. The second therapeutic approach is looking at the benefits of PARP-inhibition
to prevent DNA repair, thus forcing cellular suicide (Rouleau et al., 2010). Several studies are
actually looking into the second approach to see if PARP inhibitors can be utilized as therapeutic
agents for single-agent or combination therapy as anticancer treatment. PARP inhibitors would
work as therapeutic agents due to their capacity to block poly(ADP-Ribose) enzymes, these
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enzymes help repair DNA damage. PARP inhibition assists with tumor growth limitation, and
inhibition of angiogenesis (Rosado et al., 2013). More recently PARP inhibitors have undergone
clinical trials to assess their use against BRCA-defective cancer cells. PARP’s interaction with
BRCA1 and BRCA2 proteins is crucial, if its excision repair was inhibited these types of cancer
cells would be unable to repair DNA, thus leading to tumor death (Rosado et al., 2013). As trials
continue to progress the medical applications for PARP inhibitors will broaden. While it is
apparent that PARP plays an integral role in DNA-mediated cellular death, what role it plays is
highly dependent upon the inducer of damage. The paradox is highly perplexing, in some instances
of DNA damage typically lower scaled PARP plays a protective role in staving off cell death. In
other instances when extensive DNA damage occurs PARP promotes cellular death. PARP’s
ability to undertake duel-function roles is highly dependent upon cell type, DNA damage extent,
cascade activation, and cellular target. PARP as a consumer of energy (ATP / NAD) and nature
as a DNA binding molecule are highly dependent: balance of which determines cellular survival
(Herceg & Wang, 2001).
Cardio toxicity of alkyling agents like cyclophosphamide are tied directly to the
administrated treatment amount of a single dose vs. a lifetime dose response effect (Kumar,
Dhankhar, Kar, Shrivastava, & Shrivastava, 2011). Much like previous studies acrolein exposure
for this study was assessed with a consistent cell density. This is due to other assessments proving
acrolein-induced toxicity was highly dependent upon dose received by each cell verses the
treatment concentrated administered to each well. Additionally fold controls were used to assess a
base line to establish cytotoxicity in treatment groups (Kern & Kehrer, 2002). The range of
treatment groups for acrolein were too high to be considered clinically relevant, but were good for
assessing acute high-dose exposure at the cellular level. In terms of PARP analysis no inhibitor
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intervention was applied, only time points of acrolein exposure were assessed. Poly (ADP-ribose)
synthesis can only occur through members of the PARP family, primarily by PARP-1. When
DNA damage is present poly(ADP-Ribosyl)ation levels will be high, absent of DNA damage the
levels will be very low (Bouchard et al., 2003). Analysis performed on PARP activity were used
to help determine the extent of damage done through the treatment of acrolein. PARP activity
increased as acrolein-treatment concentration increased to a point due to greater damage under
taken by the cells. In higher acrolein-treatment groups activity dropped off, most likely due to
inhibition of PARP to activation apoptotic pathways. Further analysis of acrolein exposure timepoints could give a broader understanding to the activation of PARP due to cytotoxicity. Based
on this analysis a trend was reviled that implied PARP activity would linearly decrease across all
dose groups as acrolein exposure periods increased. Most likely this would be due to increased
damages caused by the prolonged exposure periods.
In terms of cytotoxic assessment this investigation had a few suggestions to offer for future
assessment. For MTT analysis this investigation believes that a tighter standard deviation could be
achieved through increasing the replication of trials. Additionally one analysis was discarded due
to use of a pre-aliquoted DIQ being utilized. This aliquot had been stored at -20°C, its use showed
no differences between vehicle and controls in any treatment groups. Further testing was
performed using fresh 1,5-dihydroxyisoquinoline, each sequential analysis performed showed a
protective factor. Thus it is recommended to prepare fresh PARP inhibitor prior to each trial as
pre-aliquoted freezer storage impacted the ability for DIQ to reduce cytotoxic effects. When
analyzing the AST assay this investigation proved the importance of insuring high protein in
samples run for analysis. Poor performance in AST assays particularly from a poor signal strength
can be attributed to loading with low protein (Huang et al., 2006). For future analysis it is
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recommended to increase the protein load by increasing the cellular density and decreasing the
replacement medium for which to collect the AST lysate. This investigation used a 96-well treated
plate, increasing to a 48-well or 24-well with a plating density of 50,000-75,000 cells per well
should help all treatment groups to be read above detection. When initially running AST analysis,
a 24-hour wash out period was utilized, this resulted in a flat-line for AST signals, resulting in all
treatment groups to fall below the detection limit. Two trial runs were performed to determine time
points and lysate medium volumes. Time points assessed were 2-hour, 4-hour, 6-hour, 8-hour
respectively. A linear relationship was established with AST activity increasing until the 6-hour
peak mark, with activity levels severely reduced at 8-hour reading. Additionally analysis was
performed to determine the medium volume which would help concentrate AST the best, 35 µl
was determined to be the best volume which would allow for adequate coverage of plate wells thus
not skewing results by having cell death attributed to hypoxia vs. treatment. Further analysis
should be performed and investigate the levels of caspase-3 as it is a key marker for apoptosis.
Cellular fate post-exposure to an alkylating agent is determined through the metabolic state of the
cell. Inactivation of PARP by caspase-mediated cleave is responsible for initializing apoptosis
having helped block the pathway of necrosis cell death (Jin & El-Deiry, 2005). Since caspase-3 is
responsible for the cleavage of poly(ADP-Ribose) polymerase (PARP) during apoptosis,
comparative measures of PARP, cleaved PARP, and caspase-3 activity could give a more in-depth
analysis to the level of acrolein-induced cytotoxicity. Cleaved PARP is induces apoptosis through
chromatin condensation, membrane blebbing and DNA-fragmentation. (Cohen, 1997) Westernblot analysis was performed using Caspase-3 and PARP antibodies to determine MW present in
samples. Positive identification of PARP, Cleaved-PARP and Caspase-3 occurred.
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Digital

imaging of nitrocellulose membranes proved inadequate resolution for inclusion in this report. Use
of more advanced imaging techniques in the future could produce a higher quality resolution.
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CHAPTER FIVE:
CONCLUSION
This investigation assessed the role of the enzyme poly (ADP-ribose) polymerase (PARP)
and PARP inhibitors in acrolein induced toxicity using the established toxicological H9c2 (2-1)
cardiomyoblast in-vitro model. Through this analysis the characterization of PARP’s role in
cytotoxicity was able to be determined. In low concentration PARP activation is suggestive of
electrophilic damage of DNA. The inactivation of PARP at higher concentrations imitates
apoptotic mediation through activation of caspase-3. Further analysis is needed to investigate
PARP cleavage as a marker for apoptosis. Cytotoxic assessment showed that pre-incubation with
a PARP inhibitor had a positive trend in increasing cellular viability in all treatment groups,
statistically significant protection was reached in 25 µM & 50 µM treatment groups. MTT activity
showed a positive trend across all treatment groups for increasing when DIQ groups were
compared to vehicle groups. AST activity in isolated cell lysates for many lower treatment groups
were unable produce a strong enough signal for data characterization of DIQ’s protective qualities
due samples falling below detection limits. Higher treatment groups which were read above
detection showed a positive trend when compared to vehicle groups, but statistical significance
was unreached. Further analysis is needed to investigate methodological changes which could lead
to an increase in signal strength for AST detection. Further analysis is also needed to investigate
more clinically relevant levels of acrolein against longer exposure periods. Testing using the H9c2
cardiomyocyte cell line represents an appropriate model for characterizing the role of PARP in
acrolein-mediated cytotoxicity.
30

REFERENCES
Aboutabl, M. E., & El-Kadi, A. O. (2007). Constitutive expression and inducibility of CYP1A1
in the H9c2 rat cardiomyoblast cells. Toxicol In Vitro, 21(8), 1686-1691.
doi:10.1016/j.tiv.2007.07.002
American Cancer Society. (2016). Breast Cancer. Retrieved from
http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics
Angsutararux, P., Luanpitpong, S., & Issaragrisil, S. (2015). Chemotherapy-Induced
Cardiotoxicity: Overview of the Roles of Oxidative Stress. Oxid Med Cell Longev, 2015.
Arumugam, N., Thanislass, J., Ragunath, K., Niranjali Devaraj, S., & Devaraj, H. (1999).
Acrolein-induced toxicity--defective mitochondrial function as a possible mechanism.
Arch Environ Contam Toxicol, 36(4), 373-376.
Bouchard, V. J., Rouleau, M., & Poirier, G. G. (2003). PARP-1, a determinant of cell survival in
response to DNA damage. Exp Hematol, 31(6), 446-454.
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72,
248-254.
Chan, M. K. (1984). Cyclophosphamide: a drug profile. J Assoc Pediatr Oncol Nurses, 1(3), 3033.
Cohen, G. M. (1997). Caspases: the executioners of apoptosis. Biochem J, 326 ( Pt 1), 1-16.

31

Conklin, D. J., Haberzettl, P., Jagatheesan, G., Baba, S., Merchant, M. L., Prough, R. A., . . .
Bhatnagar, A. (2015). Glutathione S-transferase P protects against cyclophosphamideinduced cardiotoxicity in mice. Toxicol Appl Pharmacol, 285(2), 136-148.
doi:10.1016/j.taap.2015.03.029
Dadfarmay, S., Berkowitz, R., & Kim, B. (2012). Irreversible end-stage cardiomyopathy
following a single dose of cyclophosphamide. Congest Heart Fail, 18(4), 234-237.
doi:10.1111/j.1751-7133.2011.00279.x
Dantzer, F., Schreiber, V., Niedergang, C., Trucco, C., Flatter, E., De La Rubia, G., . . . de
Murcia, G. (1999). Involvement of poly(ADP-ribose) polymerase in base excision repair.
Biochimie, 81(1-2), 69-75.
de Jonge, M. E., Huitema, A. D., Rodenhuis, S., & Beijnen, J. H. (2005). Clinical
pharmacokinetics of cyclophosphamide. Clin Pharmacokinet, 44(11), 1135-1164.
doi:10.2165/00003088-200544110-00003
Faroon, O., Roney, N., Taylor, J., Ashizawa, A., Lumpkin, M., & Plewak, D. (2008). Acrolein
health effects. Toxicology and industrial health, 24(7), 447-490.
Herceg, Z., & Wang, Z. Q. (2001). Functions of poly(ADP-ribose) polymerase (PARP) in DNA
repair, genomic integrity and cell death. Mutat Res, 477(1-2), 97-110.
Hescheler, J., Meyer, R., Plant, S., Krautwurst, D., Rosenthal, W., & Schultz, G. (1991).
Morphological, biochemical, and electrophysiological characterization of a clonal cell
(H9c2) line from rat heart. Circ Res, 69(6), 1476-1486.
Hong, S. J., Dawson, T. M., & Dawson, V. L. (2004). Nuclear and mitochondrial conversations
in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci, 25(5), 259-264.
doi:10.1016/j.tips.2004.03.005

32

Huang, X.-J., Choi, Y.-K., Im, H.-S., Yarimaga, O., Yoon, E., & Kim, H.-S. (2006). Aspartate
aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT) detection
techniques. Sensors, 6(7), 756-782.
Jin, Z., & El-Deiry, W. S. (2005). Overview of cell death signaling pathways. Cancer Biol Ther,
4(2), 139-163.
Kaplan, J., O'Connor, M., Hake, P. W., & Zingarelli, B. (2005). Inhibitors of poly (ADP-ribose)
polymerase ameliorate myocardial reperfusion injury by modulation of activator protein1 and neutrophil infiltration. Shock, 23(3), 233-238.
Kehrer, J. P., & Biswal, S. S. (2000). The molecular effects of acrolein. Toxicol Sci, 57(1), 6-15.
Kern, J. C., & Kehrer, J. P. (2002). Acrolein-induced cell death: a caspase-influenced decision
between apoptosis and oncosis/necrosis. Chem Biol Interact, 139(1), 79-95.
Kimes, B. W., & Brandt, B. L. (1976). Properties of a clonal muscle cell line from rat heart. Exp
Cell Res, 98(2), 367-381.
Kumar, S., Dhankhar, N., Kar, V., Shrivastava, M., & Shrivastava, S. (2011). Myocardial injury
provoked by cyclophosphamide, protective aspect of hesperidin in rats. Int J Res Pharm
Biomed Sci, 2(3), 1288-1296.
Langford, C. (1997). Complications of cyclophosphamide therapy. European archives of otorhino-laryngology, 254(2), 65-72.
Mohammad, M. K., Avila, D., Zhang, J., Barve, S., Arteel, G., McClain, C., & Joshi-Barve, S.
(2012). Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress,
mitochondrial dysfunction and oxidative stress. Toxicol Appl Pharmacol, 265(1), 73-82.
doi:10.1016/j.taap.2012.09.021

33

Riss, T. L., Moravec, R., Niles, A., Benink, H., Worzella, T., & Minor, L. (2004). Cell viability
assays.
Rodriquez-Hernandez, C. O., Muro, A. L. , Gonzalez, F. J. , Guerrero-Barrera, A. L. . (2014).
Cell Culture: History, Development and Prospects. International Journal of Current
Research and Academic Review, 2(12), 188-200. Retrieved from
https://www.researchgate.net/publication/269932638_Cell_culture_History_Developmen
t_and_Prospects
Rosado, M. M., Bennici, E., Novelli, F., & Pioli, C. (2013). Beyond DNA repair, the
immunological role of PARP-1 and its siblings. Immunology, 139(4), 428-437.
doi:10.1111/imm.12099
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010). PARP
inhibition: PARP1 and beyond. Nat Rev Cancer, 10(4), 293-301. doi:10.1038/nrc2812
Sardao, V. A., Oliveira, P. J., Holy, J., Oliveira, C. R., & Wallace, K. B. (2007). Vital imaging of
H9c2 myoblasts exposed to tert-butylhydroperoxide--characterization of morphological
features of cell death. BMC Cell Biol, 8, 11. doi:10.1186/1471-2121-8-11
Sladek, N. E. (1973). Bioassay and relative cytotoxic potency of cyclophosphamide metabolites
generated in vitro and in vivo. Cancer Res, 33(6), 1150-1158.
Yu, S. W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., . . . Dawson, V.
L. (2002). Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by
apoptosis-inducing factor. Science, 297(5579), 259-263. doi:10.1126/science.1072221
Zordoky, B. N., & El-Kadi, A. O. (2007). H9c2 cell line is a valuable in vitro model to study the
drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods, 56(3), 317-322.
doi:10.1016/j.vascn.2007.06.001

34

